US2005191314A1PendingUtilityA1

Prevention and treatment of amyloidogenic disease

62
Assignee: NEURALAB LTDPriority: Dec 2, 1997Filed: Apr 15, 2005Published: Sep 1, 2005
Est. expiryDec 2, 2017(expired)· nominal 20-yr term from priority
Inventors:Dale B. Schenk
A61P 37/00A61P 43/00A61P 25/00A61P 25/28A61K 2039/55555A61K 9/4866C07K 2319/00A61K 2039/505A61K 38/1709C07K 16/18A61K 2039/605A61K 9/0019A61K 47/646A61K 9/7023A61K 2039/55505A61K 2039/53A61K 2039/55572C07K 14/4711A61K 38/193A61K 9/2009A61K 31/739C07K 2317/24C07K 2317/567A61K 9/2031A61K 2039/55566A61K 2039/55577A61K 2039/6037A61K 9/2054A61K 31/00A61K 39/0007A61K 39/00
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is Aβ peptide or an antibody thereto.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising a mixture of Aβ oligomers capable of generating an immune response thereto, wherein the composition is a vaccine or a component of a vaccine.  
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the immune response comprises antibodies that bind to the mixture.  
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the composition is capable of therapeutically treating Alzheimer's disease.  
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the composition is capable of prophylactically treating Alzheimer's disease.  
     
     
         5 . The pharmaceutical composition of  claim 1 , further comprising an adjuvant.  
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the adjuvant comprises alum.  
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein the adjuvant comprises monophosphoryl lipid (MPL).  
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein the adjuvant comprises  Quillaja Saponaria  Molina (QS21).  
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the adjuvant comprises GM-CSF.  
     
     
         10 . The pharmaceutical composition of  claim 1 , wherein the adjuvant comprises M-CSF.  
     
     
         11 . The pharmaceutical composition of  claim 1 , which comprises at least 50 μg of the Aβ peptide.  
     
     
         12 . The pharmaceutical composition of  claim 1 , which comprises at least 100 μg of the Aβ peptide.  
     
     
         13 . The pharmaceutical composition of  claim 1 , wherein the Aβ oligomers consist of amino acid residues 1-42.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.